Key result
LncRNA MIAT is abnormally expressed in diabetic complications and competitively binds microRNAs to regulate gene expression, highlighting its potential as a therapeutic target.
Why the study?
LncRNA MIAT is abnormally expressed in various diseases, especially diabetic complications, but summarizing its pathway and regulatory mechanisms is needed to identify new therapeutic targets.
LncRNA MIAT plays a significant role in the pathogenesis of diabetic complications by acting as a competitive endogenous RNA, highlighting its potential as a novel therapeutic target.
Supports exploration of MIAT-targeted therapies in diabetic complications; leaves open clinical efficacy pending randomized trials.
Long non-coding RNA (LncRNA) refers to a large class of RNAs with over 200 nucleotides that do not have the function of encoding proteins. In recent years, more and more literature has revealed that lncRNA is involved in manipulating genes related to human health and disease, playing outstanding biological functions, which has attracted widespread attention from researchers. The newly discovered long-stranded non-coding RNA myocardial infarction-related transcript (LncRNA MIAT) is abnormally expressed in a variety of diseases, especially in diabetic complications, and has been proven to have a wide range of effects. This review article aimed to summarize the importance of LncRNA MIAT in diabetic complications, such as diabetic cardiomyopathy, diabetic nephropathy, and diabetic retinopathy, and highlight the latest findings on the pathway and mechanism of its participation in regulating diabetic complications, which may aid in finding new intervention targets for the treatment of diabetic complications. LncRNA MIAT competitively binds microRNAs to regulate gene expression as competitive endogenous RNAs. Thus, this review article has reviewed the biological function and pathogenesis of LncRNA MIAT in diabetic complications and described its role in diabetic complications. This paper will help in finding new therapeutic targets and intervention strategies for diabetes complications.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a review in Diabetic complications. LncRNA MIAT was evaluated. LncRNA MIAT is abnormally expressed in diabetic complications and competitively binds microRNAs to regulate gene expression, highlighting its potential as a therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: